Corvus Pharmaceuticals, Inc. — Q1 2023 Form 10-Q
Business context and reporting period. Clinical-stage biopharmaceutical company developing oncology and immune-modulating drug candidates. This unaudited report covers the three months ended March 31, 2023, with comparisons to Q1 2022. Corvus has not generated product revenue and manages its business as one operating segment.
Key financial metrics
| Metric | Q1 2023 | Q1 2022 / prior date |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $4.6 million | $5.1 million |
| General and administrative expense | $2.0 million | $2.3 million |
| Total operating expenses | $6.6 million | $7.4 million |
| Net loss | $7.9 million; $0.17 per share | $8.3 million; $0.18 per share |
| Net cash used in operating activities | $8.1 million | $6.4 million |
| Cash, cash equivalents and marketable securities | $34.5 million | $42.3 million at Dec. 31, 2022 |
| Total assets / stockholders’ equity | $58.2 million / $48.9 million | $68.2 million / $56.1 million at Dec. 31, 2022 |
Margins are not meaningful because the company reported no revenue. No borrowing debt is reported; liabilities primarily include operating lease obligations, totaling about $2.3 million. Accumulated deficit was $315.6 million at quarter-end.
Material changes and operating results
- Net loss narrowed by $0.4 million year over year, while operating expenses declined by $0.8 million. Higher interest income, reflecting increased interest rates, contributed to the improvement; the larger loss from Angel Pharmaceuticals partly offset it.
- R&D spending shifted among programs: CPI-818 expense increased to $1.6 million from $0.4 million, while ciforadenant declined to $0.2 million from $0.5 million and mupadolimab declined to $0.1 million from $1.7 million.
- Operating cash use increased to $8.1 million from $6.4 million. Cash and marketable securities fell $7.8 million from year-end; investing activities provided $4.6 million, largely due to net maturities of securities.
Outlook, risks and unusual items
- Management said available cash, cash equivalents and short-term marketable securities should fund planned operations for at least 12 months from issuance of the financial statements. It also said current resources are not expected to fund all ongoing and planned development through commercialization; additional financing will be needed.
- On March 28, 2023, Corvus replaced its prior Jefferies at-the-market agreements with a new agreement for up to $90 million gross proceeds, subject to a 3% sales commission. No shares were sold under the program in Q1. The company’s public float was below $75 million, triggering “baby shelf” limits on amounts issuable under its shelf registration statement.
- For CPI-818, management reported preliminary Phase 1/1b results in relapsed T-cell lymphomas and identified an absolute lymphocyte count above 900 as a potential response-associated biomarker; eligible trial patients are now required to meet that threshold. Results remain preliminary and may change. Corvus planned to request an FDA meeting on a registration Phase 3 design, anticipated in Q3 2023.
- Ciforadenant is being studied in a Phase 1b/2 kidney cancer combination trial. Corvus was prioritizing CPI-818 and ciforadenant and waiting to initiate a potential Phase 2 mupadolimab trial; Angel Pharmaceuticals continued mupadolimab development in China.
- Principal risks include clinical-trial failure or delay, regulatory uncertainty, dependence on third-party manufacturers and research organizations, competition, and the need for additional capital. The company reported no material legal proceedings. Management stated disclosure controls were effective as of March 31, 2023.
Important facts for investors to verify
- Cash runway assumptions, quarterly operating cash use, and the timing and amount of required financing.
- Actual proceeds, dilution, and available issuance capacity under the $90 million ATM, including applicable baby shelf restrictions.
- Updated CPI-818 trial enrollment, response durability, biomarker validation, safety data, and FDA feedback on a Phase 3 plan.
- Progress and funding needs for ciforadenant and mupadolimab, including Angel Pharmaceuticals’ development activity and the value of Corvus’s equity-method investment.
- Any future changes in trial timelines, manufacturing supply, regulatory requirements, or Nasdaq listing compliance.